TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9507253

Group type: EXPERIMENTAL
Intervention: Excimer laser trephination
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mechanical trephination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study: 8000941

Group type: EXPERIMENTAL
Intervention: Head covering with two terry cloth towels until UBT reached 37 degrees C
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no head covering)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Head covering
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Shiverers (both groups)
Number of subjects: 40
Study: 1771604

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 micrograms twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7025675

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic calf compression
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 119
Study: 30771791

Group type: EXPERIMENTAL
Intervention: Mitochondrial agents, N-acetylcysteine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28126360

Group type: EXPERIMENTAL
Intervention: 1.2g/d omega-3 PUFA (n=38)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 79
Study: 26396135

Group type: EXPERIMENTAL
Intervention: Test formulation of ALC hydrochloride 590 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulation of ALC hydrochloride 590 mg
Number of subjects: 0
Study: 23637314

Group type: EXPERIMENTAL
Intervention: Shelter residence
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Demographic and standardized measures of IPV, trauma, and depression
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Trauma symptoms, housing instability, and ethnicity
Number of subjects: 113
Study: 21429452

Group type: EXPERIMENTAL
Intervention: Serum IL-18 level
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: AFP level
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75

Group type: COMPARATOR
Intervention: Disease control (HCV-related chronic liver disease)
Number of subjects: 75
Study: 19479183

Group type: EXPERIMENTAL
Intervention: STEMI patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: CAD patients
Number of subjects: 23
Study: 17719296

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin 400 U/kg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Recombinant human erythropoietin 100 U/kg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Recombinant human erythropoietin 200 U/kg
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 15118425

Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 20
Study: 11444885

Group type: EXPERIMENTAL
Intervention: Subcutaneous carbon-dioxide insufflations (10 treatments) and standard physical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard physical treatment only
Number of subjects: 0
Study: 9745404

Group type: EXPERIMENTAL
Intervention: TRH + GHRP-2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GHRP-2 alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GHRH + GHRP-2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo or TRH
Number of subjects: 20
Study: 8111939

Group type: EXPERIMENTAL
Intervention: Decubitus position for 30 min after epidural blood patch
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Decubitus position for 60 min after epidural blood patch
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Decubitus position for 120 min after epidural blood patch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 3207854

Group type: EXPERIMENTAL
Intervention: ibuprofen SR 800 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg followed by ibuprofen SR 800 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: conventional ibuprofen tablets (2 x 400 mg)
Number of subjects: 12
Study: 29208322

Group type: COMPARATOR
Intervention: NPPV alone (NPPV-a)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: NPPV with nasal cannula at 15L/min (NPPV-nc)
Number of subjects: 64
Study: 28803012

Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus rhamnosus SD11
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fermented milk containing Lactobacillus bulgaricus
Number of subjects: 43
Study: 26654223

Group type: EXPERIMENTAL
Intervention: Behaviour change techniques (BCTs) training for practice nurses
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Complex physical activity consultations
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Participation in the trial
Number of subjects: 11
Study: 23764108

Group type: EXPERIMENTAL
Intervention: Training intervention focusing on existential issues and nurses' perceived confidence in communication.
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-training group (control).
Number of subjects: 102
Study: 21982663

Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program
Number of subjects: 2604

Group type: COMPARATOR
Intervention: Non-QI group (control)
Number of subjects: 2604
Study: 18304310

Group type: EXPERIMENTAL
Intervention: Training and follow-up supervision (experimental group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No training and supervision (control group)
Number of subjects: 79
Study: 17154777

Group type: EXPERIMENTAL
Intervention: Directed forgetting instruction with varying forget signal delays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Default instruction to remember
Number of subjects: 0
Study: 12708395

Group type: EXPERIMENTAL
Intervention: Netilmycin in combination with Cefasolin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gentamycin in combination with Cefasolin
Number of subjects: 50
Study: 11885180

Group type: EXPERIMENTAL
Intervention: Mobile implants at placement
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Non-mobile implants at placement
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: HA-coated implants (mobile at placement)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Non-HA-coated implants (mobile at placement)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: HA-coated implants (non-mobile at placement)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Non-HA-coated implants (non-mobile at placement)
Number of subjects: 800
Study: 8967866

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1421911

Group type: EXPERIMENTAL
Intervention: Single daily dose of 4 mg/kg of trimethoprim coupled with 17.5 mg/kg of sulphadiazine for 3 days (group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Single daily dose of 4 mg/kg of trimethoprim coupled with 17.5 mg/kg of sulphadiazine for 10 days (group 2)
Number of subjects: 40
Study: 3880875

Group type: EXPERIMENTAL
Intervention: Allopurinol and adenine therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30914464

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)
Number of subjects: 452
Study: 28865065

Group type: EXPERIMENTAL
Intervention: 5000 ppm fluoride rinse
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1500 ppm fluoride rinse
Number of subjects: 12
Study: 27427807

Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Literature control
Number of subjects: 131
Study: 24924647

Group type: EXPERIMENTAL
Intervention: Reflecting on romantic partner
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reflecting on opposite-sex friend
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reflecting on morning routine
Number of subjects: 0
Study: 22608783

Group type: EXPERIMENTAL
Intervention: Bevacizumab in AViTA (77 patients)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Bevacizumab in AVOREN (59 patients)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo in AViTA
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo in AVOREN
Number of subjects: 264
Study: 19732250

Group type: EXPERIMENTAL
Intervention: Parenting groups (Incredible Years programme and SPOKES programme)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (information helpline)
Number of subjects: 112
Study: 16998861

Group type: EXPERIMENTAL
Intervention: Symptom Severity Index and Symptom Impact Index (SSI/SII)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Bristol Female Lower Urinary Tract Symptom Questionnaire (BFLUTS)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Kings Health Questionnaire (KHQ)
Number of subjects: 291
Study: 15766298

Group type: EXPERIMENTAL
Intervention: Extended-release carbamazepine (ERC-CBZ)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 12392342

Group type: EXPERIMENTAL
Intervention: MAPS (Manchester Active Position Seat)
Number of subjects: 4
Study: 10638770

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide pulse therapy (750 mg/m2) for 12 months; concurrent prednisone (10 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral cyclophosphamide (2-2.5 mg/kg/day) for 12 months; concurrent prednisone (10 mg/day)
Number of subjects: 16
Study: 7781174

Group type: EXPERIMENTAL
Intervention: PGE2 vaginal gel every 12 hours, initial dose of 2 mg followed by two additional doses at 12 hour intervals if not in active labor.
Number of subjects: 70

Group type: COMPARATOR
Intervention: PGE2 vaginal gel every 6 hours, initial dose of 1 mg followed by 2 mg at 6 hour intervals for a maximum of two additional doses if not in active labor.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: PGE2 vaginal gel every 12 hours
Number of subjects: 70

Group type: COMPARATOR
Intervention: PGE2 vaginal gel every 6 hours
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 1969770

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.5 mg.kg‐1 after d-tubocurarine 0.05 mg.kg‐1, intubation after 60 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.5 mg.kg‐1 after d-tubocurarine 0.05 mg.kg‐1, intubation after 90 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.01 mg.kg‐1 followed by 0.1 mg.kg‐1, intubation after 60 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.01 mg.kg‐1 followed by 0.1 mg.kg‐1, intubation after 90 seconds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vecuronium (Group IV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium (Group III)
Number of subjects: 0
Study: 6986040

Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30705244

Group type: EXPERIMENTAL
Intervention: Remotely delivered cognitive-behavioural approaches (CBAs)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Personalised exercise programme interventions
Number of subjects: 375

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 375
Study: 28945667

Group type: EXPERIMENTAL
Intervention: Immediate Group (n = 29)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Early Group (n = 29)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Delayed Group (n = 73)
Number of subjects: 85
Study: 26414902

Group type: EXPERIMENTAL
Intervention: early adenotonsillectomy (eAT)
Number of subjects: 322

Group type: COMPARATOR
Intervention: watchful waiting/supportive care (WWSC)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: eAT
Number of subjects: 322

Group type: COMPARATOR
Intervention: WWSC
Number of subjects: 322
Study: 23286246

Group type: EXPERIMENTAL
Intervention: 200 mg/day palmvitee supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22120944

Group type: EXPERIMENTAL
Intervention: Topical oxytocin gel for seven days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gel for seven days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical oxytocin gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 20
Study: 19480654

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 6800 International Units daily for one year
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3)
Number of subjects: 200
Study: 17318994

Group type: EXPERIMENTAL
Intervention: Mobile Cardiac Outpatient Telemetry (MCOT)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Standard Loop Event Monitor (LOOP)
Number of subjects: 266
Study: 15496221

Group type: COMPARATOR
Intervention: Thioridazine 50 mg alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Thioridazine 50 mg with donepezil 5 mg daily for 2 weeks
Number of subjects: 12
Study: 12536625

Group type: EXPERIMENTAL
Intervention: Captopril (1 mg.kg‐1, oral) pretreatment 48 hours before operation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no special treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Captopril group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 9879046

Group type: EXPERIMENTAL
Intervention: Combined magnetic field (CMF) bone growth stimulation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no CMF stimulation)
Number of subjects: 31
Study: 8024908

Group type: EXPERIMENTAL
Intervention: ketorolac 0.75 mg kg‐1 i.v.
Number of subjects: 42

Group type: COMPARATOR
Intervention: morphine 0.1 mg kg‐1 i.v. and metoclopramide 0.15 mg kg‐1
Number of subjects: 42
Study: 2811970

Group type: EXPERIMENTAL
Intervention: Standard dose of lithium (serum concentration 0.8 to 1.0 mmol per liter)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Low dose of lithium (serum concentration 0.4 to 0.6 mmol per liter)
Number of subjects: 94
Study: 825780

Group type: EXPERIMENTAL
Intervention: Sequential therapy (surgery followed by chemotherapy, second-look laparotomy, and subsequent whole abdominal radiation)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (external radiation and single alkylating agent chemotherapy)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Triple chemotherapy (cyclophosphamide, dactinomycin, and 5-fluorouracil)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Single agent therapy with melphalan
Number of subjects: 97
Study: 31981556

Group type: EXPERIMENTAL
Intervention: Self-Help Plus
Number of subjects: 694

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 694
Study: 29882635

Group type: EXPERIMENTAL
Intervention: Systolic Extinction Training (SET)
Number of subjects: 62

Group type: COMPARATOR
Intervention: OT-TENS
Number of subjects: 62

Group type: COMPARATOR
Intervention: AE-BRT
Number of subjects: 62
Study: 28422632

Group type: EXPERIMENTAL
Intervention: Sense training 3×/wk for 6 wk (18 hr)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 17
Study: 26710810

Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA
Number of subjects: 53

Group type: COMPARATOR
Intervention: Gd‐DTPA
Number of subjects: 53
Study: 23718705

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 grams/day for 5 days) with chloroquine (3 days of oral weight-based dosing)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Chloroquine and primaquine (standard doses)
Number of subjects: 12
Study: 21743431

Group type: EXPERIMENTAL
Intervention: Emdogain®
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 26
Study: 19706349

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl iontophoretic transdermal system (ITS)
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia (IV PCA)
Number of subjects: 1305
Study: 16700803

Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg SC
Number of subjects: 686

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 686
Study: 14499423

Group type: EXPERIMENTAL
Intervention: THC (20 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: THC-morphine (20 mg THC + 30 mg morphine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morphine (30 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: THC-morphine
Number of subjects: 12
Study: 10682226

Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg (active control)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8979174

Group type: EXPERIMENTAL
Intervention: Baylor square
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Double square
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sahrmann technique
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Scapular position
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 49
Study: 8104273

Group type: EXPERIMENTAL
Intervention: Citalopram 10-20 mg daily for 3 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2868412

Group type: EXPERIMENTAL
Intervention: Thiopental (30 mg/kg)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Standard brain‐oriented intensive care
Number of subjects: 262
Study: 28815639

Group type: COMPARATOR
Intervention: VVZ‐149 (0.25-8 mg/kg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: VVZ‐149 (4-7 mg/kg, twice daily for 3 days)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: VVZ‐149 (0.5-8 mg/kg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 27464616

Group type: EXPERIMENTAL
Intervention: Gastric band with gastro-gastric suture (GGS)
Number of subjects: 706

Group type: COMPARATOR
Intervention: Gastric band without gastro-gastric suture (no GGS)
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Body mass index <40 kg/m at baseline
Number of subjects: 706
Study: 25154831

Group type: EXPERIMENTAL
Intervention: Composite comorbidity/age score
Number of subjects: 3033

Group type: EXPERIMENTAL
Intervention: Age ≥ 40 years
Number of subjects: 3033

Group type: COMPARATOR
Intervention: High-dose conditioning regimens
Number of subjects: 3033

Group type: COMPARATOR
Intervention: Nonmyeloablative conditioning regimens
Number of subjects: 3033

Group type: COMPARATOR
Intervention: Age groups (20-39, 40-49, 50-59, ≥ 60)
Number of subjects: 3033
Study: 22490102

Group type: EXPERIMENTAL
Intervention: Authentic small-group preclerkship teaching format
Number of subjects: 133

Group type: COMPARATOR
Intervention: Non-authentic teaching formats
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Number of patients seen
Number of subjects: 133
Study: 20633184

Group type: EXPERIMENTAL
Intervention: H. pylori eradication before starting NSAID therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H. pylori eradication alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors (PPI) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 0
Study: 19127908

Group type: EXPERIMENTAL
Intervention: Neck clustered needling (acupuncture group)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Alprazolam (medication group)
Number of subjects: 76
Study: 15939391

Group type: EXPERIMENTAL
Intervention: Collagen plugs
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Silicone plugs
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 24
Study: 12856384

Group type: EXPERIMENTAL
Intervention: Furosemide gastroretentive dosage form (60 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Immediate-release tablet
Number of subjects: 14
Study: 11520471

Group type: EXPERIMENTAL
Intervention: Rapid Personality Assessment Schedule (PAS‐R)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Full version of the PAS (PAS‐I ‐ ICD version)
Number of subjects: 155
Study: 8660083

Group type: EXPERIMENTAL
Intervention: Ibuprofen (20 mg/kg/24 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol (50 mg/kg/24 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both Ibuprofen and Paracetamol
Number of subjects: 0
Study: 1853990

Group type: EXPERIMENTAL
Intervention: Group 1: exclusion and treatment of symptomatic and asymptomatic infected children
Number of subjects: 4180

Group type: EXPERIMENTAL
Intervention: Group 2: exclusion and treatment of symptomatic infection only
Number of subjects: 4180

Group type: EXPERIMENTAL
Intervention: Group 3: exclusion and treatment of symptomatic infection, treatment of asymptomatic infection in the center
Number of subjects: 4180

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 4180
Study: 6352281

Group type: EXPERIMENTAL
Intervention: Ciclazindol 10‐(m‐chlorophenyl)‐2, 3, 4, 10‐tetrahydropyrimide (1, 2 alpha) indol‐10‐ol hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metformin 500 mg b.d.
Number of subjects: 0
Study: 31626021

Group type: EXPERIMENTAL
Intervention: Bodyweight exercises (including Cook hip lift)
Number of subjects: 20
Study: 29952159

Group type: EXPERIMENTAL
Intervention: low‐flu/val: 10 mg/20 mg
Number of subjects: 20
Study: 27530532

Group type: EXPERIMENTAL
Intervention: 500 mg of oral levofloxacin for 3 days
Number of subjects: 801

Group type: COMPARATOR
Intervention: Intravenous antibiotics for 3 days
Number of subjects: 801
Study: 25379850

Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 320

Group type: COMPARATOR
Intervention: Chemoradiotherapy + surgery
Number of subjects: 320
Study: 22098272

Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg/d for 4 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 23
Study: 21286411

Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 64
Study: 17602085

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 600 mg daily for 26 weeks
Number of subjects: 45
Study: 16133127

Group type: EXPERIMENTAL
Intervention: Imipramine (mean daily dose of 248 mg, dose range 50-450 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective serotonin re-uptake inhibitors (SSRIs)
Number of subjects: 0